dc4

DC4 can be used to synthesize antibody-drug conjugate (ADC), which is an ADC cytotoxin. DC4 can be used for targeted therapy of tumors.

DC4 crosslinker, an 18Å mass spectrometry-cleavable crosslinking reagent, features two intrinsic positive charges facilitating the fragmentation of cross-linked peptides into their constituent peptides through collision-induced dissociation or in-source decay. Initial fragmentation leads to cleavage adjacent to the positive charges, enabling the identification of cross-linked peptides as pairs of ions with precise mass separation. Furthermore, the resultant intact peptide fragments can undergo further fragmentation, producing a sequence of b- and y-ions for peptide identification.

The IC50s of DC4SMe on Ramos, Namalwa and HL60 / s cancer cells were 1.9 nM, 2.9 nM and 1.8 nM, respectively. DC4SMe can be used for targeted therapy of tumors. DC4SMe is a phosphate prodrug of the cytotoxic DNA alkylating agent DC4 and can be used in the

DC41SMe is a DC1 derivative that is cytotoxic to Ramos, Namalwa and HL60 / s with IC50s ranging from 18-25 pM. DC1 is a simplified analogue of CC-1065, an antibody conjugate of cytotoxic DNA alkylation molecules, used for targeted treatment of cancer.

DC41 is a derivative of DC1. DC1 is a simplified analogue of CC-1065, an antibody conjugate of cytotoxic DNA alkylating agents, used for targeted treatment of cancer.

The IC50 of DC44SMe for Ramos, Namalwa and HL60 / s cancer cells was 2.0 nM, 2.8 nM and 1.9 nM, respectively. DC44SMe can be used for targeted treatment of cancer. DC44SMe is a phosphate prodrug of DC44 and can be used in the synthesis of antibody-drug co

LDC4297 (LDC044297) is a potent and selective CDK7 inhibitor.

LDC4297 hydrochloride is a selective and efficient CDK7 inhibitor with broad-spectrum antiviral activity. It inhibits herpesvirus, adenovirus, poxvirus, retrovirus, and positive-strand RNA viruses. It can be used for research on viral infections.

DC432 is a cell-permeable peptide that serves as an inhibitor of N-terminal Xaa-Pro-Lys N-methyltransferase 1 (NTMT1; IC50 = 0.054 µM), capable of binding to both NTMT1 and NTMT2 with dissociation constants (Kds) of 0.3 and 1 µM, respectively. It effectively inhibits the N-terminal dimethylation of regulator of chromosome condensation 1 (RCC1) by NTMT1 at concentrations of 10 and 50 µM in cell-free assays. Furthermore, at a concentration of 100 µM, DC432 diminishes the trimethylation of the RCC1 SPKRIA motif in HCT116 cells.

AZA197 (AZA-197) is a selective Cdc42 inhibitor. It acts by inhibiting primary colon cancer growth and prolonging survival in a preclinical mouse xenograft model by downregulation of PAK1 activity.

Bofutrelvir (FB2001) is a SARS-CoV-2 3CL protease inhibitor with antiviral activity for the study of novel coronavirus pneumonia (COVID-19) infections.

LDC4297 is a potent and selective CDK7 inhibitor with an IC50 of 0.13 nM.

ML241 is a potent and selective inhibitors of p97 ATPase.ML241 inhibits degradation of a p97-dependent but not a p97-independent proteasome substrate in a dual-reporter cell line. ML241 may be a novel agent for the chemotherapy of cancer, and provide a rationale for developing pathway-specific p97 inhibitors.

CUDC-427 (GDC-0917) is an orally bioactive and pan antagonist of inhibitor of apoptosis proteins(IAPs). CUDC-427 can be used in research on cancers.

MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).

NMS-873 is a potent and selective allosteric inhibitor of VCP/p97.

ZCL278 is a selective Cdc42 GTPase inhibitor.

DBEQ (JRF 12) is a selective, potent, reversible, and ATP-competitive p97 inhibitor.

MLS-573151 is a selective inhibitor of GTPase Cdc42(EC50 of 2 μM). It is inactive against other GTPases family members, such as Rab2, Rab7, H-Ras, Rac1, Rac 2 and RhoA wild-type. MLS-573151 acts by blocking the binding of GTP to Cdc42.

EHop-016 is a specific Rac GTPase inhibitor with IC50 of 1.1 μM for Rac1 in MDA-MB-231 and MDA-MB-435 cells, equally effective inhibition for Rac3.

ML141 (CID-2950007) is an effective, specific and reversible non-competitive inhibitor of Rho family GTPase cdc42 (IC50: 200 nM).

KRCA-0008 is an effective and specific ALK/Ack1 inhibitor (IC50: 12/4 nM); displays drug-like properties without hERG liability.

GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.

ML240 is a selective, ATP-competitive p97 inhibitor.